Document is current
Any future updates will be listed below
-
Authors
Fontanilles, Maxime https://orcid.org/0000-0003-4350-7349
Heisbourg, Jean-David
Daban, Arthur
Di Fiore, Frederic
Pépin, Louis-Ferdinand
Marguet, Florent
Langlois, Olivier
Alexandru, Cristina
Tennevet, Isabelle
Ducatez, Franklin
Pilon, Carine
Plichet, Thomas
Mokbel, Déborah
Lesueur, Céline
Bekri, Soumeya
Tebani, Abdellah
-
Funding
Funding for this research was provided by:
ARTC
- License Information
-
More Information
Article History
Received: 7 July 2024
Accepted: 6 September 2024
First Online: 12 October 2024
Declarations
:
: This study is ancillary to the prospective GLIOPLAK trial (ClinicalTrial.gov NCT02617745, registered 11/30/2015). GLIOPLAK has been approved by the French National Committee for the Protection of Persons (RCB ID 2015-A00377-42).
: All the patients gave their written and informed consent. All De-identified and signed forms are available upon request.
: MF declares income received for research purposes from Servier Foundation, benefits for interventions from Seagen and Novocure, and payment of congress fees from Gilead and Pfizer. The authors declare no conflict of interest.
